Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer

Memorial Sloan Kettering Cancer Center (MSK)

Status and phase

Completed

Phase 2

Conditions

Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer

Treatments

Drug: OSI-774: erlotinib, TarcevaTM

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00590902

02-010

Details and patient eligibility

About

The primary objective of this study is to determine the major objective response rate of OSI-774 in participants with unresectable or metastatic bronchioloalveolar cell variant of non-small cell lung cancer.

This study is a Phase II study. The first study of OSI-774 was done to evaluate what dose should be given to patients with cancer has been completed. The purpose of this research study is to see whether this experimental treatment, called OSI-774, can cause a type of non-small cell lung cancer to stop growing or shrink. This study is sponsored by a company called Genentech, and is being done at Memorial Hospital, as well as other cancer centers around the country interested in developing new drugs for the treatment of this type of cancer.

Enrollment

81 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Either bronchioloalveolar cell carcinoma or a variant thereof after review
Clinical stage IIIB (malignant pleural or pericardial effusion) or IV or recurrent/medically inoperable disease
Measurable or evaluable indicator lesions
No prior or one chemotherapy regimen for NSCLC
Three weeks since last chemotherapy, and three weeks since prior radiation therapy to a major bone-marrow containing area
Karnofsky performance status > or = to 80% OR ECOG performance status ≤ or = to 1
Life expectancy > or = to 8 weeks
Adequate hematologic, renal and/or hepatic function: WBC > or = to 3,000/ul, hemoglobin > or = to 9.0 g/dl, platelet count > or = to 100,000/ul, total bilirubin < or = to 1.0 mg/dl, AST < than or = to 2.5 X UNL, creatinine < or = to 1.5 mg/dl or Clcr > or = to 55ml/min.
Effective contraception

Exclusion criteria

Prior exposure to OSI-774 or other treatments targeting the HER family axis (e.g.-trastuzumab, ZD1839, C225, etc.)
Two or more prior chemotherapy regimens
Concurrent active cancer
Uncontrolled central nervous system metastases (i.e. any known CNS lesion which is radiographically unstable, symptomatic and/or requiring escalating doses of corticosteroids)
Pregnant or lactating women
Malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin
Prior systemic cytotoxic chemotherapy for other malignant disease
Significant medical history or unstable medical condition (unstable systemic disease: congestive heart failure, recent MI, unstable angina, active infection, uncontrolled hypertension).